A less invasive treatment strategy to prevent intracranial hemorrhage in fetal and neonatal alloimmune thrombocytopenia.
about
Antenatal interventions for fetomaternal alloimmune thrombocytopeniaAntenatal interventions for fetomaternal alloimmune thrombocytopeniaNeonatal thrombocytopenia: causes and managementEuropean collaborative study of the antenatal management of feto-maternal alloimmune thrombocytopeniaNeonatal alloimmune thrombocytopenia in the Irish population: a discrepancy between observed and expected cases.Prenatal management of alloimmune thrombocytopenia of the fetus.Will it ever be possible to balance the risk of intracranial haemorrhage in fetal or neonatal alloimmune thrombocytopenia against the risk of treatment strategies to prevent it?Experiences with fetomaternal alloimmune thrombocytopenia at a Swedish hospital over a 10-year period.Effect of maternal anti-HPA-1a antibodies and polyclonal IVIG on the activation status of vascular endothelial cells.Survey of the use and clinical effectiveness of HPA-1a/5b-negative platelet concentrates in proven or suspected platelet alloimmunization.Collaborative study to establish the first international standard for quantitation of anti-HPA-1a.Reactivity of T cells from women with antibodies to the human platelet antigen (HPA)-1a to peptides encompassing the HPA-1 polymorphism.Prospective epidemiologic study of the outcome and cost-effectiveness of antenatal screening to detect neonatal alloimmune thrombocytopenia due to anti-HPA-1a.Predictive value of sequential maternal anti-HPA-1a antibody concentrations for the severity of fetal alloimmune thrombocytopenia.Vaginal delivery for fetuses at risk of alloimmune thrombocytopenia?The management of feto-maternal alloimmune thrombocytopenia: report of three cases.Advances in the management of alloimmune thrombocytopenia.Management and outcome of 200 cases of fetomaternal alloimmune thrombocytopenia.HPA-1a antibody potency and bioactivity do not predict severity of fetomaternal alloimmune thrombocytopenia.Fetomaternal alloimmune thrombocytopenia: the questions that still remain.Developing recombinant HPA-1a-specific antibodies with abrogated Fcgamma receptor binding for the treatment of fetomaternal alloimmune thrombocytopenia.Lower-dose intravenous immunoglobulins for the treatment of fetal and neonatal alloimmune thrombocytopenia: a cohort study.Current perspectives on fetal and neonatal alloimmune thrombocytopenia - increasing clinical concerns and new treatment opportunities.Antibodies against human platelet alloantigens and human leucocyte antigen class 1 in Saudi Arabian multiparous women and multi-transfused patients.Antenatal treatment of fetal alloimmune thrombocytopenia: a current perspective.Expression of a single-chain human leukocyte antigen-DRA/DRB3*01:01 molecule and differential binding of a monoclonal antibody in the presence of specifically bound human platelet antigen-1a peptide.
P2860
Q24234535-5E59FCA4-3E55-46FC-BAC8-E53969E037B3Q24245104-03772737-11F5-4A7E-ACB8-89B11D36727AQ24673677-8CC93717-C870-48DA-9D36-486C3EFC4DE8Q28185478-0FB37EC9-FFF0-4F10-98C4-70EC2A785DECQ33341730-B85E7B8D-3BFD-4F9B-94DE-C03A5CC871BCQ33346704-F5A78BC9-0D0A-412A-8E57-78970526E80CQ33348098-17B0FE54-8A6F-42FB-9B4B-FC6AC67DBF30Q33349447-555082DF-1C4B-4E4E-89DD-5CB62E250B07Q33361251-F191F68E-4E9C-40DF-B3CD-48E0E0324BB5Q33363893-6337D298-A57E-4B61-A778-BF5B087CD1D0Q33367845-A53ED4D9-B79D-420E-92A7-723FA4C17A2BQ33368580-7ECF2FD3-4CC3-4DA7-AE70-0A54421B5B13Q33369697-56619431-4833-4D25-BE56-4AC876E5B67CQ33370198-9EE6B037-14DF-4A04-957D-7896C695A35EQ33371873-83B2699B-950A-44AD-8F16-479BB2025FB6Q33372607-596A0BF0-5820-4C1D-A77B-BA0279ED2722Q33373910-1BD95D85-A7F8-413F-805D-C69890294795Q33375062-BF19EC7A-6A63-4115-B34B-08C57E235B10Q33375634-E52F7B9F-A28B-4818-81AB-3D262AAD7BFEQ33376261-F8070705-6B4F-46B4-9C08-CE7525281487Q33380492-CDA0C502-9F7C-4B9B-BAB0-5D989A87DFB0Q33433678-A3838953-AFD6-4793-9124-383AAF36850DQ33441520-8F0CA743-F2DC-45BE-94AA-B0908590C159Q35681149-F485195E-2B24-4D04-A3F2-65D9D5C970C4Q42392796-64948AA2-B307-4733-B624-096BDF348EC1Q54486514-DF553100-5B95-4AE7-BCB0-BE1007CC5BC5
P2860
A less invasive treatment strategy to prevent intracranial hemorrhage in fetal and neonatal alloimmune thrombocytopenia.
description
2001 nî lūn-bûn
@nan
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
A less invasive treatment stra ...... l alloimmune thrombocytopenia.
@ast
A less invasive treatment stra ...... l alloimmune thrombocytopenia.
@en
A less invasive treatment stra ...... l alloimmune thrombocytopenia.
@nl
type
label
A less invasive treatment stra ...... l alloimmune thrombocytopenia.
@ast
A less invasive treatment stra ...... l alloimmune thrombocytopenia.
@en
A less invasive treatment stra ...... l alloimmune thrombocytopenia.
@nl
prefLabel
A less invasive treatment stra ...... l alloimmune thrombocytopenia.
@ast
A less invasive treatment stra ...... l alloimmune thrombocytopenia.
@en
A less invasive treatment stra ...... l alloimmune thrombocytopenia.
@nl
P2093
P356
P1476
A less invasive treatment stra ...... l alloimmune thrombocytopenia.
@en
P2093
P304
P356
10.1067/MOB.2001.116727
P407
P577
2001-09-01T00:00:00Z